About
Technology
Issues
FAQ
Links
Official Page
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.